logo Creation made simple
Beautifully designed
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut convallis tempor orci vitae vehicula. Aliquam in ullamcorper lacus.
Follow & share
Search:
Infallible Pharma | INFADOBU INJECTION
20957
portfolio_page-template-default,single,single-portfolio_page,postid-20957,edgt-core-1.0.1,ajax_fade,page_not_loaded,,hudson-ver-1.8, vertical_menu_with_scroll,smooth_scroll,side_menu_slide_from_right,blog_installed,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

INFADOBU INJECTION

INFADOBU INJECTION


Brand Name : Infadobu


Generic Name : Dobutamine Injection IP 250 mg/5ml


Pack Size : 5 x 5 ml Ampule


Dosage Form : Injection


Strength : 50mg/ml


Therapeutic indications : The primary action of dobutamine is to augment cardiac contractility by stimulating the β1 receptors of the heart. It is a direct-acting agent.
This is indicated for adults who require inotropic support in the treatment of low output cardiac failure associated with myocardial infarction, open heart surgery, cardiomyopathies, septic shock and cardiogenic shock. Dobutamine can also increase or maintain cardiac output during positive end expiratory pressure (PEEP) ventilation. Dobutamine may also be used for cardiac stress testing as an alternative to exercise in patients for whom routine exercise testing cannot be satisfactorily performed. This use of dobutamine should only be undertaken in units which already perform exercise stress testing and all normal care and precautions required for such testing are also required when using dobutamine for this purpose.


Pharmacotherapeutic group : Adrenergic and dopaminergic agents


ATC code : C01CA07


Pharmacodynamic properties : Dobutamine is a sympathomimetic agent with direct effects on beta -adrenergic receptors, which confer upon it a prominent inotropic action on the heart. Dobutamine differs from dopamine in not having the specific dopaminergic properties of dopamine which induce renal mesenteric vasodilatation; however, it has some alpha and beta -agonist properties. It is reported not to have indirect sympathomimetic effects. The inotropic action of dobutamine on the heart is associated with less cardiac accelerating effect than that of isoprenaline.

Date

February 12, 2022

Share